Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Guanine nucleotide-binding protein G(z) subunit alpha (GNAZ) is a membrane-bound GTPase forming the alpha subunit of the heterotrimeric G(z) protein, linked to seven-transmembrane (7-TM) receptors. It mediates signal transduction in systems insensitive to pertussis toxin, and may play a role in the ionic balance within the cochlea. GNAZ acts by switching between inactive GDP-bound and active GTP-bound forms in response to GPCR activation, influencing downstream effectors such as adenylyl cyclase. Diseases such as night blindness, thrombocytopenia-absent radius syndrome, and certain cancers are associated with its altered function or expression
Inhibition of adenylyl cyclase activity (leading to decreased cellular cAMP production); Signal transduction via heterotrimeric G protein pathways (G protein-coupled receptor activation); Pertussis toxin-insensitivity (unaffected by ADP-ribosylation by pertussis toxin)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Guanine nucleotide-binding protein G(z) subunit alpha (GNAZ).